- Home
- FATE vs TLSI Comparison
FATE vs TLSI Comparison
Compare FATE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- TLSI
- Stock Information
- Founded
- FATE 2007
- TLSI 2010
- Country
- FATE United States
- TLSI United States
- Employees
- FATE N/A
- TLSI N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- FATE Health Care
- TLSI Health Care
- Exchange
- FATE Nasdaq
- TLSI Nasdaq
- Market Cap
- FATE 108.2M
- TLSI 158.0M
- IPO Year
- FATE 2013
- TLSI N/A
- Fundamental
- Price
- FATE $0.94
- TLSI $5.30
- Analyst Decision
- FATE Hold
- TLSI Strong Buy
- Analyst Count
- FATE 9
- TLSI 6
- Target Price
- FATE $5.50
- TLSI $11.75
- AVG Volume (30 Days)
- FATE 3.4M
- TLSI 40.1K
- Earning Date
- FATE 03-05-2025
- TLSI 03-27-2025
- Dividend Yield
- FATE N/A
- TLSI N/A
- EPS Growth
- FATE N/A
- TLSI N/A
- EPS
- FATE N/A
- TLSI N/A
- Revenue
- FATE $13,631,000.00
- TLSI $26,891,000.00
- Revenue This Year
- FATE N/A
- TLSI $61.29
- Revenue Next Year
- FATE N/A
- TLSI $53.21
- P/E Ratio
- FATE N/A
- TLSI N/A
- Revenue Growth
- FATE N/A
- TLSI 67.90
- 52 Week Low
- FATE $0.87
- TLSI $3.50
- 52 Week High
- FATE $7.70
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- FATE 37.74
- TLSI 47.92
- Support Level
- FATE $0.87
- TLSI $4.60
- Resistance Level
- FATE $1.03
- TLSI $5.68
- Average True Range (ATR)
- FATE 0.12
- TLSI 0.33
- MACD
- FATE -0.01
- TLSI -0.08
- Stochastic Oscillator
- FATE 13.12
- TLSI 56.00
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.